Australia Health

ReNerve (ASX:RNV) has secured a convertible note funding facility of up to $5 million to support its commercialisation strategy.

ResMed (ASX:RMD) signed an agreement to sell its MatrixCare software business to private equity firm Frazier Healthcare Partners.

Imugene (ASX:IMU) secured firm commitments to raise $11.1 million via a share placement to fund its cancer clinical trials.

Argent BioPharma (ASX:RGT) executed a binding transaction framework for the exclusive global licensing of its epilepsy asset CannEpil.

Entropy Neurodynamics (ASX:ENP) reported that all patients in its initial trial cohort achieved a 74% reduction in binge eating episodes.

Osteopore (ASX:OSX) secured market access to Saudi Arabia to commercialise its 3D-printed craniofacial implants in partnership with Zimmer Biomet (NYSE:ZBH).

Clinical-stage company Syntara (ASX:SNT) announced that 20 of 30 patients recorded lower brain inflammation from baseline.

ReNerve (ASX:RNV) obtained marketing approval for its NervAlign Nerve Cuff in Indonesia

OncoSil Medical (ASX:OSL) has completed its Humanitarian Device Exemption application submission to the US FDA.

Echo IQ (ASX:EIQ) executed an exclusive agreement to license up to 1 million de-identified echocardiography studies from Advara HeartCare.

Genetic Signatures (ASX:GSS) received no advance notification regarding a 10.2% stake acquisition by BCAL Diagnostics (ASX:BDX).

Imugene (ASX:IMU) announced a second complete response within 24 hours in its concurrent combination trial cohort.